"o Núcleo de Pesquisa Clinica do Rio Grande do Sul (NPCRS) realiza pesquisas na área da saúde. Os projetos tem como objetivo avaliar novos tratamentos com o foco na melhora da qualidade de vida dos pacientes. Trabalhamos na área de Endocrinolgia (diabetes, dislipidemia, obesidade), cardiologia, reumatologia, neurologia, pneumologia e ginecologia."

During the past decade, Núcleo de Pesquisa Clínica do Rio Grande do Sul conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 3 clinical trials were completed, i.e. on average, 15.8% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 3 clinical trials were completed. i.e. 18.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Núcleo de Pesquisa Clínica do Rio Grande do Sul" #1 sponsor was "Eli Lilly and Company" with 6 trials, followed by "Janssen Research & Development, LLC" with 4 trials sponsored, "Allergan" with 3 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored and "Amgen" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Núcleo de Pesquisa Clínica do Rio Grande do Sul" #1 collaborator was "Nektar Therapeutics" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Núcleo de Pesquisa Clínica do Rio Grande do Sul" are "Crohn's Disease" (3 trials), "Diabetes Mellitus" (3 trials), "Gastroparesis" (3 trials), "Obesity" (3 trials) and "Depressive Disorder, Major" (2 trials). Many other conditions were trialed in "Núcleo de Pesquisa Clínica do Rio Grande do Sul" in a lesser frequency.

Most popular intervention types in "Núcleo de Pesquisa Clínica do Rio Grande do Sul" are "Drug" (17 trials), "Other" (3 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Relamorelin" (3 trials), "Tirzepatide" (3 trials), "Aticaprant" (2 trials) and "Fenebrutinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Núcleo de Pesquisa Clínica do Rio Grande do Sul" are 18 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Núcleo de Pesquisa Clínica do Rio Grande do Sul". undefined are not yet recruiting, 8 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Núcleo de Pesquisa Clínica do Rio Grande do Sul, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Núcleo de Pesquisa Clínica do Rio Grande do Sul, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".